subject: Pharmaceutical Mergers And Acquisitions- Aarkstore Enterprise- Aarkstore Enterprise [print this page] Overview Overview
Ensure merger and acquisition success - at any point in the M&A process
Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.
The past year has been marked by heightened M&A activity among companies of all sizes. Small companies are increasingly investing in large-molecule products that are expensive to produce and test in clinical trials - but in this tough economic climate, they face diminishing capital and the threat of closing. To continue their work on time-sensitive compounds, they are exploring the possibility of a company sale. On the other hand, for those companies with cash, this situation presents an opportunity to acquire attractive compounds and technology platforms at a discount.
Timelines, rankings, strategies, and deal profiles will allow you to maximize the benefits and growth opportunities of a deal:
Understand the M&A environment
Learn what is driving the acquisition strategies of top companies - and how other organizations are seeking suitors for their own sales.
Build a competitive deal-making process
Target the right deals with an M&A task force
Implement a timeline that works for both sides
Track different types of financing across deals brokered by companies of different sizes
